News
Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...
The Details: Kinder Morgan reported quarterly earnings of 28 cents per share, which beat the analyst consensus estimate of 27 ...
1h
InvestorsHub on MSNAbbott’s Q2 revenue surpasses expectations despite share declineThe healthcare leader posted adjusted earnings per share of $1.26 for the quarter, slightly above the consensus estimate of ...
Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...
StockStory.org on MSN1h
Abbott Laboratories’s (NYSE:ABT) Q2 Sales Top EstimatesHealthcare product and device company Abbott Laboratories (NYSE:ABT) in Q2 CY2025, with sales up 7.4% year on year to $11.14 ...
For CVS, Q2 earnings will be a critical inflection point. A miss could trigger a breakup or further decline, making the stock ...
International Business Machines said Thursday that it had joined forces with Moderna for a case study that evidenced quantum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results